Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation

Bone Marrow Transplantation

Volumn 28, Issue 9, 2001, Pages 821-825

  Balasubramanian, P ^a   Chandy, M ^a   Krishnamoorthy, R ^b   Srivastava, A ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Bone marrow transplantation; Busulfan; Limited sampling model; Thalassaemia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; BLOOD SAMPLING; CALCULATION; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; EVALUATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MODEL; PRIORITY JOURNAL; SAMPLING; STATISTICAL ANALYSIS; THALASSEMIA MAJOR;

ADOLESCENT; ALKYLATING AGENTS; AREA UNDER CURVE; BETA-THALASSEMIA; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; INFANT; MALE; MODELS, THEORETICAL; SAMPLING STUDIES; SOFTWARE; TRANSPLANTATION CONDITIONING;

EID: 0035193194     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703245     Document Type: Article

References (24)

1. Marrow transplantation for acute non-lymphocytic leukaemia after treatment with busulfan and cyclophosphamide
2. Engraftment rates related to busulfan/cyclophosphamide dosages for displacement marrow transplantation in 50 children
3. Bone marrow transplantation in patients with thalassemia
4. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics
5. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
6. Disposition of high dose busulfan in pediatric patients undergoing bone marrow transplantation
7. Busulfan disposition below the age of three: Alteration in children with lysosomal storage disease
8. The impact of obesity and disease on busulfan oral clearance in adults
9. Pharmacokinetics of high dose busulfan in relation to age and chronopharmacology
10. Chronopharmacology of high dose busulfan in children
11. Busulfan pharmacokinetics in bone marrow transplant patients: Is therapeutic drug monitoring warranted?
12. Influence of prophylactic anticonvulsant therapy on high dose busulfan kinetics
13. Association of busulfan area under the curve with veno-occlusive disease following BMT
14. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukaemia: Phase I dose escalation of busulfan based on targeted plasma levels
15. Thalassaemia: Clinical management
16. The pathology, diagnosis and treatment of hepatic veno-occlusive disease: Current status and novel approaches
17. Plasma busulfan levels influence rejection in bone marrow transplantation for homozygous beta thalassaemia
18. Pharmacokinetics of oral busulfan in children with thalassemia undergoing BMT
19. High performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol
20. Pharmacokinetic pharmacodynamic data analysis system for the PC
21. An improved limited sampling method for individualized busulfan dosing in bone marrow transplantation in children
22. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?
23. Busulfan kinetics and limited sampling model in children with leukaemia and inherited disorders
24. A program package for simulation and parameter estimation in pharmacokinetic systems